Here, the authors report on the substantial clinical response and reduction in cutaneous toxicity in a case series of BRAFV600E primary brain cancers treated with dual BRAF/MEK inhibitor therapy.
Sorafenib, the first agent developed to target BRAF mutant melanoma, is a multi-kinase inhibitor that was approved by the FDA for therapy of kidney and subsequently liver cancer, and is currently in clinical trials for thyroid, lung and brain cancer.